The Latest Cardiac and Vascular News
Company focusing on consumer revenue growth with reduced cost structure Pharmaceutical assets may be monetized through licensing or sale Other strategic alternatives under consideration Board of Directors restructured in connection with new strategy HONOLULU, Aug. 31, 2021 /PRNewswire/ — Cardax, Inc., announced today that it is refocusing its business strategy on its […]
– Operating loss decreased vs. Q1 2020 – Net loss increased vs. Q1 2020 – ZanthoSyn® revenues decreased vs. Q1 2020 – Company pursuing multiple funding opportunities HONOLULU, May 14, 2021 /PRNewswire/ — Cardax, Inc. (OTCQB:CDXI) reported its Q1 2021 results. Highlights: Financial Results. Operating loss decreased from $906,031 in Q1 2020 to $771,312 in Q1 2021 […]
HONOLULU, Jan. 14, 2020 /PRNewswire/ — Cardax, Inc. (OTCQB:CDXI) today announced it will effect a 200-for-1 reverse stock split of its issued and outstanding common stock. Pursuant to the Certificate of Amendment to the Company’s Certificate of Incorporation filed with the Secretary of State of Delaware, the reverse stock split will be effective at 12:01 […]
– CHASE clinical trial interim review demonstrated beneficial changes in markers of cardiovascular health – Composition of matter and use patents filed to extend U.S. and worldwide patent coverage to 2039-2040 – ZanthoSyn® sales rebounded — Q3 2019 sales five times Q2 2019, with return to normal inventory sell-in patterns […]
Pre-Specified Interim Review Demonstrated Beneficial Changes in Markers of Cardiovascular Health – CRP, LDL, total cholesterol, triglycerides, oxidized LDL, and blood pressure reduced – Interim results support excellent safety profile – Enrollment continues HONOLULU, Sept. 23, 2019 /PRNewswire/ — Cardax, Inc. (OTCQB: CDXI) today announced results from the pre-specified interim review of its […]
– Maxim Group to serve as sole book running manager on a firm commitment basis – Funds to be used primarily for pharmaceutical development – Concurrent Nasdaq uplisting planned HONOLULU, Aug. 14, 2019 /PRNewswire/ — Cardax, Inc. (OTCQB:CDXI) announced today that it filed a registration statement on Form S-1 with the Securities […]
HONOLULU, Oct. 2, 2018 /PRNewswire/ — Cardax, Inc. (OTCQB: CDXI) has launched its Cardiovascular Health Astaxanthin Supplement Evaluation (CHASE) clinical trial targeting cardiovascular inflammatory health. The first subject was dosed on September 19, 2018. The randomized, double-blind, placebo-controlled CHASE clinical trial will evaluate the effect of low-dose and high-dose ZanthoSyn®, Cardax’s premium astaxanthin supplement, on cardiovascular health, as measured […]
